The reasons for these conflicting results may be largely associated with certain technical issues, such as tissue fixation (duration of, and time between surgical removal and, fixation), tissue processing protocol, different antibodies to HER2, IHC staining protocols, and stringent criteria for the assessment of HER2 staining; and to a lesser extent, with the genetic background of cervical adenocarcinomas in Chinese populations. Here, ERBB2 is linked to cervical adenocarcinoma.